Search results
Pfizer (PFE) Phase III DMD Gene Therapy Study Misses Goal
Zacks· 2 days agoFree Report) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular dystrophy (“DMD”) failed to meet ...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 days agoAnalysts at Mizuho and William Blair say Pfizer’s setback removes any threat of...Motilal Oswal Financial Services analysts say in a research report....
Thermo Fisher's (TMO) New Launch Supports Full Lab Automation
Zacks via Yahoo Finance· 22 hours agoPrice Performance In the past year, TMO shares have rallied...You can see the complete list of...
FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug
Investor's Business Daily· 5 days agoShares rose a fraction in after-hours action. Eli Lilly Stock: Risks Are Key Donanemab, like Biogen...
Bristol Myers (BMY) Gets FDA Nod for Label Expansion of Augtyro
Zacks via Yahoo Finance· 18 hours agoThe FDA approves Bristol Myers' (BMY) cancer drug Augtyro for the treatment of adult and pediatric...
Cathie Wood's ARK trades PagerDuty, Roblox stock on Thursday By Investing.com
Investing.com· 1 day agoCathie Wood's ARK trades PagerDuty, Roblox stock on Thursday
Ultragenyx wins surrogate endpoint debate, securing green light to seek FDA approval of gene therapy
FierceBiotech· 2 days agoUltragenyx Pharmaceutical's work to get the FDA to recognize a biomarker as a surrogate endpoint looks to have paid off. With the agency agreeing the biomarker is a reasonable surrogate endpoint ...
Analysts reset Nvidia stock price targets amid split, Dow entry talk
TheStreet.com· 5 days agoNvidia shares will begin trading on a split-adjusted basis Monday but remain the world's third most-valuable stock. Nvidia shares edged higher Monday into the AI leader's ...
The 'Impressive' Results That Sent This Top 1% Player To A Record
Investor's Business Daily· 3 days agoThe company is working on a treatment called del-brax for patients with facioscapulohumeral muscular...
Ultragenyx executive sells over $440k in company stock By Investing.com
Investing.com· 2 days agoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) has reported a significant stock transaction by one of...
